Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Gilead & MSD's Once-Weekly HIV Treatment Meets Phase 3 Endpoints
Gilead and MSD's novel once-weekly oral HIV pill combining islatravir and lenacapavir achieves Phase 3 clinical trial endpoints, preparing for regulatory filing.
FDA Expands Pfizer's Hympavzi Approval to More Hemophilia Patients
The FDA approves an expanded label for Pfizer's Hympavzi, a breakthrough subcutaneous non-factor treatment for hemophilia A and B patients with inhibitors.
Clinical Cancer Trials Help Boost Long-Term Cancer Survivorship Statistics
Dr. Jennifer Diamond discusses how advanced clinical cancer trials introduce critical cellular therapies to improve post-treatment quality of life.
Advanced Breast Cancer Clinical Trials: Gedatolisib Nearly Doubles PFS
Dr. Hurvitz presents Phase 3 VIKTORIA-1 trial data showing gedatolisib nearly doubles progression-free survival in PIK3CA+ advanced breast cancer.
AI Drug Discovery and Development Boosts Phase 3 Success, Says AZ CEO
AstraZeneca CEO Pascal Soriot highlights how artificial intelligence tools optimize molecule design and predict clinical success in late-stage trials.
How Nonprofits Rescue Shelved Rare Disease Drug Pipelines From Pharma
Children’s Tumor Foundation CEO Annette Bakker discusses how the nonprofit rescues shelved rare disease drugs to accelerate clinical trial validation.
Survodutide Fatty Liver Disease Treatment Normalizes Liver Fat in Phase 3
Boehringer Ingelheim presented Phase 3 trial data showing survodutide normalized liver fat in 61% of patients with fatty liver disease (MASLD).
Travere Therapeutics Signs $1.1B Licensing Deal with Everest Medicines
Travere Therapeutics gains an exclusive license to Everest Medicines' oral BTK inhibitor civorebrutinib for rare immune kidney diseases.
UCSF Selects Filament Health Psilocybin for Alzheimer's Studies
UCSF chooses Filament Health's botanical psilocybin candidate PEX010 to explore structural markers and indicators in early-stage Alzheimer's disease.
Lonza Enhances Biologics Pipeline with GS Ori-Go Vector Platform
Lonza expands its biologics preclinical development portfolio with GS Ori-Go vector technology, reducing DNA-to-IND development timelines.
FDA Issues Warning Letter to Medline Over Bacterial Contamination
Medline Industries faces FDA regulatory actions after inspectors discover repeat bacterial contamination issues at its Waukegan manufacturing facility.
New Topical 4-Aminopyridine Gel Accelerates Burn Wound Healing
Researchers develop a breakthrough topical 4-aminopyridine (4-AP) gel that significantly accelerates burn wound healing and skin regeneration.
1
2
3
4
5
6
7
8
9
